Page 30 - FIMM_Brochure_2022

Director of FIMM,
Mark Daly
Mark Daly was appointed FIMM
Director with effect from February
2018. He joined FIMM from the Broad
Institute of MIT and Harvard and
Massachusetts General Hospital.
He is a distinguished scientist who
has made major contributions to
human genetics and genomics dur-
ing his 25-year career. His primary
research focus is the discovery of
genes involved in human disease as a
means of providing both insights for
therapeutic development as well as
improved diagnostics for individual
patients. His lab has developed many
foundational computational tools and
statistical techniques in genome map-
ping, linkage and association, and
automated interpretation of labora-
tory data. The lab has a significant
and longstanding commitment in two
major medical areas: inflammatory
bowel diseases (Crohn’s and ulcerative recognised experts sit on our Scientific Advisory Board (SAB) and evaluate
colitis) and neuropsychiatric disease
(autism and schizophrenia). He has
led international consortia for large- ulation Health and Fellow of St Cross College, University of Oxford. Members
scale gene mapping efforts in each of
these areas. With Aarno Palotie, he
has helped to design and launch the
FinnGen Project as a transformative
public-private partnership. He has au- strategy. Similarly, the HiLIFE Scientific Council provides critical advice on the
thored more than 450 peer-reviewed
manuscripts with altogether more
than 200,000 citations.
30 |
Leadership
Professor Mark Daly has been the Director of FIMM since
2018, succeeding Jaakko Kaprio (2015-2017) and founding
director Olli Kallioniemi (2007-2015). The FIMM Director
leads and monitors the research strategy and operations
of the institute and is responsible for general institute
operations, personnel administration and the implemen-
tation of HR plans, as well as the financial affairs of the
institute.
Professor Samuli Ripatti is the Vice Director of FIMM. The Vice Director sup-
ports the FIMM Director in the development of FIMM as a whole, and in the
absence or disqualification of the Director acts as his or her deputy.
Research Director Katja Kivinen leads the FIMM Technology Centre
(p. 20–24).
A FIMM steering group of Research Directors meets regularly to discuss the
scientific direction for the institute. A larger assembly consisting of group
leaders, technology centre heads, and senior scientists meets several times
per year to discuss the scientific agenda and possible challenges in relation to
achieving scientific goals.
FIMM is committed to regular international evaluation. Eight internationally-
and offer advice on the development of the institute. The chair of the SAB is
Cornelia van Duijn, Professor of Epidemiology at Nuffield Department of Pop-
of the SAB visit FIMM every other year and evaluate individual group leaders
and the overall scientific progress of the institute. These evaluations are given
considerable weight and are an integral part of the EMBL design with respect
to career progression of group leaders and overall institute direction and
scientific goals and performance of FIMM, as a whole.
FIMM – Building a Bridge from Discovery to Medicine